VSTM: Advancing selective KRAS therapies with robust clinical progress and upcoming pivotal data
The session highlighted strong commercial and clinical progress for a KRAS-mutated ovarian cancer therapy and the advancement of a selective KRAS G12D inhibitor across multiple tumor types. Upcoming data readouts and new phase III trials are expected to further validate efficacy and expand market o…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.